Table 4 Multivariate analysis for the prognostic impact of IDH mutations, PTEN deletion, MGMT methylation and EGFR amplification
N | Median Survival (MS-months) | N | Multivariate analysisa | |||
|---|---|---|---|---|---|---|
Hazard ratio | 95% Cl | p-Value | ||||
GBM | ||||||
IDH | ||||||
Mutant | 10 | 25.0 | 10 | 0.52 | 0.24–1.11 | 0.092 |
Wildtype | 241 | 10.0 | 230 | Reference | ||
Astrocytoma | ||||||
IDH | ||||||
Mutant | 42 | 14.0 | 33 | 0.22 | 0.11–0.43 | < 0.001 |
Wildtype | 52 | 114.0 | 46 | Reference | ||
GBM IDH-wildtype | ||||||
PTEN | ||||||
Deleted | 184 | 11.0 | 171 | 0.65 | 0.43–0.99 | 0.042 |
Non-Deleted | 38 | 6.0 | 34 | Reference | ||
MGMT | ||||||
Methylated | 52 | 12.0 | 46 | 0.61 | 0.42–0.88 | 0.009 |
Unmethylated | 180 | 9.0 | 159 | Reference | ||
EGFR | ||||||
Amplified | 88 | 11.0 | 82 | 0.88 | 0.65–1.18 | 0.393 |
Non- Amplified | 135 | 8.0 | 123 | Reference | ||
Astrocytoma IDH-wildtype | ||||||
PTEN | ||||||
Deleted | 18 | 8.0 | 14 | 4.48 | 1.34–14.94 | 0.015 |
Non-deleted | 17 | 29.0 | 11 | Reference | ||
MGMT | ||||||
Methylated | 9 | 3.0 | 7 | 0.69 | 0.20–2.4 | 0.555 |
Unmethylated | 31 | 16.0 | 18 | Reference | ||
EGFR | ||||||
Amplified | 14 | 14.0 | 12 | 0.71 | 0.25–2.03 | 0.522 |
Non- Amplified | 20 | 13.0 | 13 | Reference | ||